U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Submission Deadlines and Process | Rare Disease Endpoint Advancement Pilot Program
  1. Development Resources

Submission Deadlines and Process | Rare Disease Endpoint Advancement Pilot Program

The quarterly submission deadlines for proposals to the Rare Disease Endpoint Advancement Pilot Program are March 31, June 30, September 30, and December 31.  Sponsors may submit a proposal to the RDEA program on a rolling basis through June 30, 2027. FDA will review all RDEA proposals received in the preceding three-month submission cycle after each submission deadline.

RDEA Pilot Program
Quarterly proposal submission deadlines
March 31 June 30 Sept. 30 Dec. 31

FDA will select a maximum of one RDEA proposal and one alternate proposal submitted during the fourth quarter of fiscal year 2023 (July 1, 2023, through September 30, 2023).  FDA will select one primary RDEA proposal and one alternate proposal per submission quarter in FY 2024 through third quarter of FY 2027, with a maximum of three RDEA proposals per year.

Sponsors will be notified whether they will proceed to disclosure discussions or their RDEA proposal has been denied approximately 60 days after the submission deadline. For each RDEA proposal admitted to the Program, FDA will conduct an initial RDEA meeting and, if requested, up to three follow-up meetings.

How to Submit an RDEA Proposal

If you have an active Pre-IND or IND, submit your RDEA Pilot Program proposal to that application.  If you do not have an active Pre-IND or IND application number, request a pre-assigned number for your RDEA Pilot Program proposal and then submit the proposal to your newly created Pre-IND application. Instructions for electronic submission are available at Electronic Regulatory Submission and Review.

For an RDEA proposal consisting of a natural history study for which there is no associated investigational product, please reach out to RDEA.Meetings@fda.hhs.gov for additional instructions before requesting a pre-assigned application number.

Requesting a pre-assigned application number:

Additional Information:

  • All RDEA Pilot Program submissions should have “RDEA Pilot Program Submission” in the submission header.
  • In addition, please send an email to RDEA.Meetings@fda.hhs.gov providing notification that your RDEA Pilot Program proposal has been submitted to the relevant application.
Back to Top